Objective: To report 2 cases of nonoperable intracranial bleeding associated with apixaban managed by 3-factor prothrombin complex concentrate (PCC3). Case Summaries: Case 1 presented with a 1.3-cm left parieto-occipital hemorrhage and a thin subdural hematoma (SDH) on the left tentorium of the brain about 6 hours after his last dose of apixaban. Case 2 presented with a 4-mm left parafalcine SDH with time of most recent apixaban dose unknown. The patients received 24.9 to 25.5 U/kg of PCC3 with none to 1 U fresh frozen plasma (FFP) and demonstrated minimal or no progression in lesions measured by repeat computed tomography (CT) after treatment. One patient was discharged to a skilled nursing facility after 8 days; the other patient was discharged to home after 18 days. Discussion: Apixaban has no specific antidote. Current bleeding management strategies are based on expert opinion. The risks and benefits for differing strategies are unclear, and little clinical experience for managing apixaban-associated intracranial bleeding has been reported to date. These cases describe the clinical use of PCC3 to manage parieto-occipital and subdural hemorrhage associated with apixaban in events not requiring surgical intervention. Conclusion: In these 2 cases, 25 U/kg PCC3, with none to one unit FFP, ceased apixaban-associated intracranial bleeding without apparent thrombogenic complications.
Introduction
Traditionally, warfarin has been the anticoagulant of choice for outpatient use because of its efficacy in thromboembolism prevention. However, warfarin is a high-risk medication with unpredictable interpatient dosing requirements, and drug and food interactions may contribute to serious bleeding events. Direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, and rivaroxaban, introduced in recent years, address several disadvantages of warfarin anticoagulation therapy. 1 The DOACs inhibit specific components of the coagulation cascade-factor IIa by dabigatran and factor Xa by apixaban, rivaroxaban, and edoxaban 2-5 ; and they have more predictable pharmacokinetics, shorter half-lives, and less required monitoring compared to warfarin. For example, apixaban has been shown to have lower number of major bleeds in the management of nonvalvular atrial fibrillation (2.13% vs 3.09%; P < .001) 6 and treatment of venous thromboembolic events (0.6% vs 1.8%; P < .001) compared to warfarin. 7 These properties make DOACs such as apixaban an attractive option for patients who will require lifelong anticoagulation.
However, a major disadvantage of DOACs is the lack of an anticoagulation reversal agent in the acute phase. Praxbind1 (idarucizumab), the first reversal agent specific to dabigatran, was approved by the US Food and Drug Administration (FDA) in 2015 and works by binding to the anticoagulant with an affinity that is higher than that of dabigatran and thrombin to neutralize the anticoagulant effect. 8 Andexanet alfa (Portola Pharmaceuticals, San Francisco, California) is a promising reversal agent for DOACs that are factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), in ongoing phase III clinical trials. 9 As of this writing, management of lifethreatening bleeds in patients taking DOACs that inhibit factor Xa rely primarily on case reports, in vitro studies, and clinical judgment. 10, 11 In the following case reports, we present the use of 3-factor prothrombin complex concentrate (PCC3) with or without fresh frozen plasma (FFP) for the management of subdural hematoma (SDH) not indicated for surgical intervention in patients taking apixaban for nonvalvular atrial fibrillation.
Case Presentations Case 1
An 85-year-old male with height and weight measuring 71 in and 80.3 kg was transferred to a level 2 emergency department (ED) from an outside hospital for higher level of care after sustaining a fall while exercising. He was found down by his family and reportedly had a syncopal episode prior to falling and hitting his head, although the patient himself was unable to recall specifics of the fall. His medical history was significant for chronic atrial fibrillation, dementia, sick sinus syndrome, coronary artery disease, and hyperlipidemia. His congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, and stroke (doubled) -vascular disease, age 65-74 years, and sex category (CHA2DS2-VASc) score was 2 and hypertension, abnormal renal and liver function, stroke, bleeding history, labile international normalized ratio, elderly >65 years, drugs or alcohol concomitantly (HAS-BLED) score was 2. His home medications were apixaban 5 mg twice daily, donepezil 10 mg after breakfast, memantine XR 28 mg daily, niacin 1000 mg daily, red yeast rice 600 mg twice daily, a multivitamin daily, and unknown daily doses of coenzyme Q10 and potassium supplements. His last dose of apixaban was about 6 hours prior to this ED encounter.
Upon arrival, the patient was confused and oriented to name only, but per family, this was his baseline. He had a Glasgow Coma Scale (GCS) of 15 and denied any other associated symptoms. Serum creatinine was 0.8 mg/dL, initial prothrombin time (PT) was 14.8 seconds (range: 11.9-15 seconds), international normalized ratio (INR) was 1.1, and heparincalibrated anti-Xa level was >1.1 IU/mL (lower limit of detection <0.1 IU/mL); all laboratory data were processed in a central laboratory. Head computed tomography (CT) from the outside hospital showed a 1.3-cm left parieto-occipital hemorrhage and a thin SDH on the left tentorium of the brain. A repeat head CT performed upon arrival to our facility revealed a 5-cm left parieto-occipital hemorrhage and an insignificant change to the SDH. There was minimal mass effect and no midline shift or herniation. Following confirmation of the worsening intraparenchymal hemorrhage, the patient received 1 U of frozen plasma. He was then transferred from the ED to the trauma intensive care unit, where he had a mild increase in confusion and began pulling out intravenous (IV) lines. At that time, 3 hours after arrival to the ED, the patient was given 2000 U (25 U/kg) of PCC3 (Profilnine-SD1; Grifols Biologicals Inc., Los Angeles, California). 10 The patient was evaluated by neurosurgery, and the injury was deemed nonoperative.
At 24 hours from admission, his PT was 14.0, INR was 1, and a repeat head CT revealed a minimal increase in hematoma volume. His neurological examination worsened on hospital day 3 (GCS 11), however, a repeat head CT was unchanged. Upon the patient's discharge to a skilled nursing facility on hospital day 8, his neurological examination had returned to baseline. Anticoagulation was to be withheld for 3 weeks per recommendation from neurosurgery.
Case 2
A 77-year-old man with height and weight measuring 64 in and 81.5 kg, respectively, presented to the ED after falling and hitting his head while at home. His medical history was significant for biventricular chronic heart failure, chronic atrial fibrillation with pacemaker, mild to moderate aortic insufficiency, seizure disorder, hyperlipidemia, obstructive sleep apnea, transient ischemic attack, stage III to IV chronic kidney disease, and mild dementia. The patient's home medications included apixaban 2.5 mg twice daily, aspirin 81 mg daily, carvedilol 12.5 mg twice daily, lamotrigine 150 mg twice daily, lovastatin 40 mg daily, furosemide 40 mg twice daily, donepezil 10 mg daily, and vitamin B complex daily. The exact time of the patient's most recent apixaban dose was unknown, but it was likely within the past 24 hours.
On admission to the ED, the patient was awake, alert, and oriented to self, time, and place. His blood pressure was 106/68 mm Hg and heart rate was 94 beats/minute. His platelet was 167 000 per mL, blood urea nitrogen was 61 mg/dL, serum creatinine was 2.76 mg/dL, hemoglobin and hematocrit were 10.5 g/dL and 32.8%, respectively. Initial coagulation assay reported an INR of 2. All laboratory data were processed in a central laboratory. The CT scan without contrast showed a 4-mm left parafalcine SDH, with no midline shift or brain herniation. There was a remote left cerebellar small vessel infarct and mild bilateral maxillary sinus disease. Apixaban and aspirin were withheld, and PCC3 (Profilnine-SD; Grifols Biologicals, Inc) 2080 U IV (25.5 U/kg total body weight) was administered to reverse the anticoagulation effects of apixaban approximately 1 hour after the patient's arrival to the ED. been on anticoagulation therapy since admission due to the presence of SDH. The DVT prophylaxis continued with compression device and aspirin 81 mg daily was started, but apixaban remained withheld. Chest X-ray on day 13 ruled out left heart failure and showed clear lungs with mild pulmonary vascular congestion.
On day 14, the patient appeared to have labored breathing and severe extremity pain. Patient was agitated with heart rate spiking up to 140 to 150 beats/minute (transient and nonsustained) from 107 beats/minute. An electrocardiogram showed atrial fibrillation at 144 beats/minute, with difficulty commenting on abnormalities to rule out pulmonary embolism. His D-dimer test returned with a value of 3344 mg/L. Doppler of his lower extremities showed no DVT. Troponin was negative at 0.028 ng/mL. Computed tomography angiogram of the chest was not performed due to his renal insufficiency. The patient experienced intermittent tachypnea and tachycardia, which were thought to be due to acute gout attack that resolved after initiation of colchicine 0.6 mg every 48 hours. It was also discovered that the patient's pacemaker was not functioning properly, so the antitachycardia pacing thresholds and the ventricular fibrillation thresholds were modified.
On hospital day 15, the neurosurgery consult found that the patient was aphasic, with right-sided weakness, as well as right facial droop, prompting concern for a stroke. However, a CT scan that day showed the SDH had decreased from 4 to 2 mm, with no signs of new bleeding or ischemia. Patient remained on aspirin 81 mg for prophylaxis. On hospital day 16, the hospitalist determined the patient to be lucid and conversational without intervention. The neurologist also confirmed the patient was no longer aphasic.
The patient was discharged on hospital day 18 with intermittent rapid atrial fibrillation and reduced 2-mm SDH. Anticoagulation therapy remained withheld pending neurologist approval, although aspirin was restarted during hospital admission.
Discussion
For major bleeding events such as intracranial hemorrhage and SDH, fast reversal is necessary to avoid the high mortality associated with delayed treatment. 13 Unfortunately, in the case of bleeding associated with apixaban and other Xa inhibitors, limited data are available to guide treatment decisions for urgent anticoagulation reversal. In these 2 patient cases, the intracranial hemorrhage could have been due to factor Xa anticoagulation or head trauma, the last dose of apixaban was determined based on patient-provided history, and the true degree of anticoagulation was unknown. Also, since the hematomas were relatively small on presentation, it is unknown whether they would have expanded further without the administration of PCC3. These real-world scenarios could have benefited from measurement of serum apixaban levels and a specific anti-Xa chromogenic assay to help guide treatment decisions, had such tests been available to the caregivers in these cases.
At this time, there is no reliable and widely available assay to determine a patient's level of anticoagulation on apixaban. Although chromogenic anti-Xa assays may be utilized for quantitative assessment of anticoagulant activity when calibrated to the specific Xa inhibitor, these tests are not widely available. In the absence of these calibrated assays, a standard chromogenic anti-Xa assay calibrated to unfractionated or lowmolecular-weight heparin may be used in a qualitative manner to assess the absence or presence of an anticoagulant effect. Additionally, there are no clinical trials that prove the efficacy and safety of potential DOAC reversal modalities. Therefore, clinicians must rely on case reports and expert opinion to determine appropriate agents and dosing. 14, 15 Selecting the appropriate procoagulant in these patients depends on several considerations, which are not limited to underlying patient risk factors, pharmacokinetic activity since the last dose given, and thromboembolic risk of each procoagulant. 10, 16 The administration of hemostatic agents may be appropriate if SDH occurred within 3 to 5 half-lives of the last dose of oral factor Xa inhibitors. 17 FFP possibly could be initially considered because it contains all clotting factors, including factor X, in naturally occurring concentrations and poses low thrombosis risk. 18 However, FFP has variable factor X component in each batch, requires time to thaw, and carries the risk of transfusion-related acute lung injury. Further, FFP would not be the preferred option for patients with renal compromise or heart failure, due to the risk of volume overload caused by the large fluid volume required to achieve adequate factor X placement. 16, 19 FFP may be useful to replace overall loss of plasma and coagulation factors.
14 However, FFP combined with PCC3 has been shown to be more effective than FFP monotherapy in reversing significant coagulopathy associated with warfarin, and no reports have been made to date regarding the value of FFP alone in reversing Xa inhibition. 20 By concentrating the coagulation factors, PCCs may be preferred over FFP due to the smaller volume, faster administration time, and predictable concentrations. Other PCC and activated PCC (aPCC) procoagulants have few studies in humans evaluating their reversal effect on apixaban anticoagulation. Evidence from animal studies may be helpful in predicting their effect in humans, with animal studies showing that PCC decreases bleeding time but not the rate of blood loss. 21 Procoagulants not only vary in their evidence for anticoagulation reversal but also in their risk of thrombin generation. A brief review of the literature reported thrombogenic rates of 0.7%, 1.8% to 3.8%, and 7% for PCC3, PCC4, and aPCC, respectively. 13, 15, [22] [23] [24] [25] [26] In addition to exposing patients to increased thromboembolic risk, depending on the clinical situation, aPCC could be considered as overly compensating since apixaban leaves factor VII intact. In contrast, PCC3 and PCC4 provide the necessary anticoagulation reversal without excess risk.
14 In comparing PCC3 to PCC4, PCC4 has a higher thrombogenic risk because it contains factor VII, which as previously discussed and depending on the clinical situation may present unnecessary risk since factor VII is not antagonized by apixaban. Containing a standardized concentration of factor X, PCC3 may balance anticoagulation reversal and safety by providing an adequate source of factor X while exposing the patient to less thromboembolic risk in cases not requiring emergency surgical intervention. 12, 26 Since clinical information to date for managing DOAC-related bleeding is comprised of case reports and case series, without comparator groups, the relative risks and benefits of the PCC products are unknown.
An important safety concern for the patient population represented in this case series involves the inherent thrombosis risk in receiving procoagulants compounded by patients' underlying medical risk factors that require baseline anticoagulation. In case 1, the patient had a history of atrial fibrillation, coronary artery disease, and hyperlipidemia, whereas the patient from case 2 had a history of aortic insufficiency, transient ischemic attack, and hyperlipidemia. Both patients were carefully monitored for signs of potential stroke, such as sudden confusion and trouble speaking or understanding speech. 27 However, these symptoms could also manifest in both patients due to comorbid history of dementia or be related to an underlying seizure disorder for case 2, which complicated assessment of neurological status and stroke symptoms. Changes in neurological status can also be due to evolving metabolic processes, especially in elderly patients. Although the 2 patients presented with different neurologic baselines, both patients expressed neurological declines on day 3 of admission. The patient from case 1 developed lethargy, whereas the patient from case 2 developed sudden confusion and loss of balance. The case 2 patient subsequently appeared aphasic, with weakness and left facial drooping. Although apixaban generally clears from the body after 48 hours, clearance may be delayed in patients with compromised renal function. Thus, the risk of thrombosis for these patients may be most concerning around day 3 postadmission, when the patients displayed symptoms of neurological decline. 28, 29 Furthermore, Dentali et al found that risk of thromboembolism is greatest within 1 to 4 days postadministration of PCC3 or PCC4, which is consistent with a potentially undetected thrombotic event due to PCC3 in both patient cases. 26 However, CT scans for both patients on day 3 indicated no changes compared to prior scans upon admission. Therefore, although both patients experienced transient neurological changes after anticoagulation reversal, none were ultimately believed by their respective teams to be sequelae of PCC3 administration. By the end of each respective hospital stay, both patients demonstrated stable physical and mental states and were discharged with plans to be followed by neurology.
In addition to receiving procoagulants, patients with SDH are also assessed for severity of bleed and whether they are candidates for surgical intervention prior to receiving reversal agents. General criteria for surgical intervention include an acute SDH with a thickness of greater than 10 mm or a CT scan that shows a midline shift greater than 5 mm, regardless of the patient's GCS. 30 In both cases described here, the patients were deemed noncandidates for surgery.
It is notable that neither patient qualified for surgery based on hematoma size. Although PCC3 25 IU/kg was sufficient to manage bleeding for these patients, some authors suggest repeat dosing or higher initial dosing for patients with continued bleeding or more severe bleeding.
14 Other authors suggest the use of PCC4 to manage oral factor Xa inhibitor-related bleeding in cases requiring emergency surgical intervention. 31 Finally as previously noted, a reversal agent for factor Xa inhibitors has not yet been FDA approved for this indication, but an agent is currently in late-phase clinical trials. Addressing apixaban and rivaroxaban reversal, andexanet alfa was studied in healthy elderly patients in the ANNEXA-A and ANNEXA-R trials, which showed an 80% to 90% reduction in antifactor Xa activity. 32 However, these trials did not study patients with an acute major bleed or those anticoagulated with other factor Xa inhibitors. These limitations were addressed in ANNEXA-4, a phase III trial that demonstrated similar efficacy in the reversal of several factor Xa inhibitors including apixaban, rivaroxaban, and enoxaparin in the setting of acute major bleeds. 9 In the 3 ANNEXA trials, about 17% of the patients developed nonneutralizing antibodies to the reversal agent, opening questions about the efficacy of a second course of andexanet alfa in patients with subsequent need for factor Xa reversal. 9, 32 If approved by the FDA, andexanet alfa will become the first and only indicated reversal agent for all factor Xa DOACs. However, given the limited clinical experience, cost concerns, and long-term efficacy of andexanet, hemostatic agents such as PCC3 may have a role in reversing acute major bleeds associated with DOACs, even after andexanet alfa becomes commercially available.
Conclusion
In this series of case reports, bleeding for 2 elderly male patients with apixaban-associated SDH not requiring surgical intervention was managed using PCC3, with little or no administration of FFP. Clinical improvement was seen in both patients after administration of a single dose of 25 U/kg of PCC3. Although PCC administration carries risk of thrombus formation, the risk may be less with PCC3 compared to alternative agents in the management of nonsurgical patients.
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